Centessa Shares Rally on Encouraging Narcolepsy-Drug Data

Dow Jones

Sep 10, 2024

By Michael Susin

Centessa Pharmaceuticals shares rose Tuesday after the company said it planned to advance its narcolepsy drug to a phase 2 trial following encouraging early study data.

In the premarket trading, shares were up 15% at $17.15. The share price has more than doubled over the past 52 weeks.

The British pharmaceutical company said interim data from a continuing phase 1 study showed its drug ORX750 restored wakefulness in acutely sleep-deprived patients.

It added the drug showed meaningful and significant improvements in mean sleep latency--the time it takes to fall asleep--at the first two doses evaluated in the maintenance-of-wakefulness test compared to placebo, along with a favorable safety profile.

The company said it plans to rapidly advance ORX750 into phase 2 study in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.

The mid-stage trial is expected to start in the fourth quarter of 2024.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

September 10, 2024 08:55 ET (12:55 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2466301544"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466301544\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2466301544?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466301544","market":"hk","top_or_hot":-1,"title":"Centessa Shares Rally on Encouraging Narcolepsy-Drug Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Michael Susin \n</p>\n<pre>\n \n</pre>\n<p>\n  Centessa Pharmaceuticals shares rose Tuesday after the company said it planned to advance its narcolepsy drug to a phase 2 trial following encouraging early study data. \n</p>\n<p>\n  In the premarket trading, shares were up 15% at $17.15. The share price has more than doubled over the past 52 weeks. \n</p>\n<p>\n  The British pharmaceutical company said interim data from a continuing phase 1 study showed its drug ORX750 restored wakefulness in acutely sleep-deprived patients. \n</p>\n<p>\n  It added the drug showed meaningful and significant improvements in mean sleep latency--the time it takes to fall asleep--at the first two doses evaluated in the maintenance-of-wakefulness test compared to placebo, along with a favorable safety profile. \n</p>\n<p>\n  The company said it plans to rapidly advance ORX750 into phase 2 study in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. \n</p>\n<p>\n  The mid-stage trial is expected to start in the fourth quarter of 2024. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Michael Susin at michael.susin@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2024 08:55 ET (12:55 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Centessa Shares Rally on Encouraging Narcolepsy-Drug Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Shares Rally on Encouraging Narcolepsy-Drug Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-09-10 20:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Michael Susin \n</p>\n<pre>\n \n</pre>\n<p>\n  Centessa Pharmaceuticals shares rose Tuesday after the company said it planned to advance its narcolepsy drug to a phase 2 trial following encouraging early study data. \n</p>\n<p>\n  In the premarket trading, shares were up 15% at $17.15. The share price has more than doubled over the past 52 weeks. \n</p>\n<p>\n  The British pharmaceutical company said interim data from a continuing phase 1 study showed its drug ORX750 restored wakefulness in acutely sleep-deprived patients. \n</p>\n<p>\n  It added the drug showed meaningful and significant improvements in mean sleep latency--the time it takes to fall asleep--at the first two doses evaluated in the maintenance-of-wakefulness test compared to placebo, along with a favorable safety profile. \n</p>\n<p>\n  The company said it plans to rapidly advance ORX750 into phase 2 study in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. \n</p>\n<p>\n  The mid-stage trial is expected to start in the fourth quarter of 2024. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Michael Susin at michael.susin@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2024 08:55 ET (12:55 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTA","symbol_name":"Centessa Pharmaceuticals plc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2466301544","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466301544","pubTimestamp":1725972900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Centessa Pharmaceuticals shares rose Tuesday after the company said it planned to advance its narcolepsy drug to a phase 2 trial following encouraging early study data.In the premarket trading, shares were up 15% at $17.15. The share price has more than doubled over the past 52 weeks.The British pharmaceutical company said interim data from a continuing phase 1 study showed its drug ORX750 restored wakefulness in acutely sleep-deprived patients.It added the drug showed meaningful and significant improvements in mean sleep latency--the time it takes to fall asleep--at the first two doses evaluated in the maintenance-of-wakefulness test compared to placebo, along with a favorable safety profile.The company said it plans to rapidly advance ORX750 into phase 2 study in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.The mid-stage trial is expected to start in the fourth quarter of 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CNTA":"Centessa Pharmaceuticals plc"},"translate_title":"Centessa股价因令人鼓舞的嗜睡症药物数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":0.9},"content_text":"By Michael Susin \n\n\n \n\n\n  Centessa Pharmaceuticals shares rose Tuesday after the company said it planned to advance its narcolepsy drug to a phase 2 trial following encouraging early study data. \n\n\n  In the premarket trading, shares were up 15% at $17.15. The share price has more than doubled over the past 52 weeks. \n\n\n  The British pharmaceutical company said interim data from a continuing phase 1 study showed its drug ORX750 restored wakefulness in acutely sleep-deprived patients. \n\n\n  It added the drug showed meaningful and significant improvements in mean sleep latency--the time it takes to fall asleep--at the first two doses evaluated in the maintenance-of-wakefulness test compared to placebo, along with a favorable safety profile. \n\n\n  The company said it plans to rapidly advance ORX750 into phase 2 study in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. \n\n\n  The mid-stage trial is expected to start in the fourth quarter of 2024. \n\n\n \n\n\n  Write to Michael Susin at michael.susin@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2024 08:55 ET (12:55 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}